165 related articles for article (PubMed ID: 29228209)
1. CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.
Bu X; Kato J; Hong JA; Merino MJ; Schrump DS; Lund FE; Moss J
Carcinogenesis; 2018 Feb; 39(2):242-251. PubMed ID: 29228209
[TBL] [Abstract][Full Text] [Related]
2. The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression.
Gao L; Liu Y; Du X; Ma S; Ge M; Tang H; Han C; Zhao X; Liu Y; Shao Y; Wu Z; Zhang L; Meng F; Xiao-Feng Qin F
Cell Death Dis; 2021 Jul; 12(7):680. PubMed ID: 34226519
[TBL] [Abstract][Full Text] [Related]
3. ADP-ribosylarginine hydrolase regulates cell proliferation and tumorigenesis.
Kato J; Zhu J; Liu C; Stylianou M; Hoffmann V; Lizak MJ; Glasgow CG; Moss J
Cancer Res; 2011 Aug; 71(15):5327-35. PubMed ID: 21697277
[TBL] [Abstract][Full Text] [Related]
4. B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses.
Verhoeven D; Grinwis L; Marsman C; Jansen MH; ; Van Leeuwen EM; Kuijpers TW
Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37419630
[TBL] [Abstract][Full Text] [Related]
5. CD38 is methylated in prostate cancer and regulates extracellular NAD
Mottahedeh J; Haffner MC; Grogan TR; Hashimoto T; Crowell PD; Beltran H; Sboner A; Bareja R; Esopi D; Isaacs WB; Yegnasubramanian S; Rettig MB; Elashoff DA; Platz EA; De Marzo AM; Teitell MA; Goldstein AS
Cancer Metab; 2018; 6():13. PubMed ID: 30258629
[TBL] [Abstract][Full Text] [Related]
6. CD38 expression by plasma cells in extramedullary multiple myeloma.
Notarfranchi L; Accardi F; Mancini C; Martella E; Bonomini S; Segreto R; Vescovini R; Palma ABD; Sammarelli G; Todaro G; Storti P; Burroughs-Garcia J; Iannozzi NT; Raimondi V; Lungu O; Ricci S; Craviotto L; Giuliani N
Haematologica; 2024 Apr; 109(4):1297-1300. PubMed ID: 37941401
[No Abstract] [Full Text] [Related]
7. IL-4 within the bone marrow: a key driver of lung tumorigenesis.
Tanaka Y
J Leukoc Biol; 2024 Apr; 115(5):791-793. PubMed ID: 38470834
[No Abstract] [Full Text] [Related]
8. Targeting CD38 alleviates tumor-induced immunosuppression.
Tai YT; Anderson KC
Oncotarget; 2017 Dec; 8(68):112166-112167. PubMed ID: 29348814
[No Abstract] [Full Text] [Related]
9. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
[TBL] [Abstract][Full Text] [Related]
10. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Casneuf T; Xu XS; Adams HC; Axel AE; Chiu C; Khan I; Ahmadi T; Yan X; Lonial S; Plesner T; Lokhorst HM; van de Donk NWCJ; Clemens PL; Sasser AK
Blood Adv; 2017 Oct; 1(23):2105-2114. PubMed ID: 29296857
[TBL] [Abstract][Full Text] [Related]
11. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab: Therapeutic asset, biological trap!
Deneys V; Thiry C; Frelik A; Debry C; Martin B; Doyen C
Transfus Clin Biol; 2018 Feb; 25(1):2-7. PubMed ID: 29336950
[TBL] [Abstract][Full Text] [Related]
13. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
Chim CS; Kumar SK; Orlowski RZ; Cook G; Richardson PG; Gertz MA; Giralt S; Mateos MV; Leleu X; Anderson KC
Leukemia; 2018 Feb; 32(2):252-262. PubMed ID: 29257139
[TBL] [Abstract][Full Text] [Related]
14. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
van de Donk NWCJ; Casneuf T; Di Cara A; Parren PW; Zweegman S; van Kessel B; Lokhorst HM; Usmani SZ; Lonial S; Richardson PG; Chiu C; Mutis T; Nijhof IS; Sasser AK
Br J Haematol; 2019 Feb; 184(3):475-479. PubMed ID: 29411874
[No Abstract] [Full Text] [Related]
15. Daratumumab for untreated multiple myeloma.
Stirrups R
Lancet Oncol; 2018 Feb; 19(2):e80. PubMed ID: 29276025
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
[TBL] [Abstract][Full Text] [Related]
18. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.
Caserta E; Chea J; Minnix M; Poku EK; Viola D; Vonderfecht S; Yazaki P; Crow D; Khalife J; Sanchez JF; Palmer JM; Hui S; Carlesso N; Keats J; Kim Y; Buettner R; Marcucci G; Rosen S; Shively J; Colcher D; Krishnan A; Pichiorri F
Blood; 2018 Feb; 131(7):741-745. PubMed ID: 29301755
[TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.
Botta C; Ciliberto D; Rossi M; Staropoli N; Cucè M; Galeano T; Tagliaferri P; Tassone P
Blood Adv; 2017 Feb; 1(7):455-466. PubMed ID: 29296961
[TBL] [Abstract][Full Text] [Related]
20. The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.
Chini EN; Chini CCS; Espindola Netto JM; de Oliveira GC; van Schooten W
Trends Pharmacol Sci; 2018 Apr; 39(4):424-436. PubMed ID: 29482842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
